KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Depreciation & Amortization (CF) (2017 - 2025)

Twist Bioscience (TWST) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 2.92% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.7 million through Dec 2025, down 16.78% year-over-year, with the annual reading at $24.9 million for FY2025, 20.93% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $6.2 million at Twist Bioscience, up from $6.0 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $8.5 million in Q3 2023, with the low at $2.5 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $5.8 million, with a median of $6.1 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) soared 99.6% in 2022, then dropped 26.94% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $3.2 million in 2021, then skyrocketed by 68.0% to $5.3 million in 2022, then surged by 54.4% to $8.2 million in 2023, then fell by 21.92% to $6.4 million in 2024, then decreased by 2.92% to $6.2 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $6.2 million, $6.0 million, and $6.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.